YWYuko Waseda

Yuko Waseda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuko Waseda has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Erlotinib‐Induced Pneumatosis Intestinalis: A Case Report and Review of Literature

    by Shunsuke Saito, Koki Nakashima, Kaede Yokoyama, Ai Takeuchi, Makiko Yamaguchi, Yukihiro Umeda, Yuko Waseda

    Pneumatosis intestinalis (PI) is a rare condition characterized by gas accumulation within the bowel wall. Although several medications have been associated with the etiopathogenesis of PI, the association between PI and epidermal growth factor receptor ( EGFR )–tyrosine kinase inhibitors (TKIs) is less recognized. We present the case of a 79‐year‐old woman who developed PI 2 months after the initiation of erlotinib. The condition improved after the discontinuation of erlotinib, suggesting a possible association between erlotinib and the development of PI. This case underscores the importance of considering PI in the differential diagnosis when patients receiving EGFR ‐TKIs present with abdominal symptoms or intramural bowel gas.


  • Open Access

    Efficacy of Jiinshihoto on Depressive Symptoms in Patients With Pulmonary Mycobacterium avium-intracellulare Complex Disease not Receiving Standard Treatment

    by Makiko Yamaguchi, Keiko Ogawa-Ochiai, Tadashi Toyama, Kosuke Kurokawa, Toshihiro Takeda, Masayuki Sato, Miho Mitsui, Akikazu Shimada, Tomoaki Sonoda, Chisato Honjo, et al.

    Background: Patients with pulmonary Mycobacterium avium - intracellulare complex (MAC) disease who cannot receive standard antimicrobial therapy have limited treatment options. Jiinshihoto, a Kampo formula (traditional Japanese herbal medicine) that is effective for chronic cough and depressive symptoms, has not been evaluated in this population. Objective: To evaluate the physical, immunological, and psychiatric effects of Jiinshihoto in patients with pulmonary MAC who were ineligible for standard antimicrobial treatment. Methods: This single-center, open-label, prospective study was conducted from March 2018 to January 2020. Patients who were not eligible for standard treatment for pulmonary MAC disease were enrolled. Jiinshihoto (3.0 g) was administered three times per day for 12 months. The primary endpoints were 3-month changes in chronic obstructive pulmonary disease assessment test (CAT) scores, body weight, and natural killer (NK) cell activity. Secondary endpoints were 3-month changes in self-rating depression scale (SDS) scores. This study was registered in the UMIN-Clinical Trials Registry (UMIN000033590). Results: In total, 24 patients were enrolled. The mean age was 68 years, and 74% were female; the mean body mass index was 19.3 kg/m 2 . Of these, 23 patients completed the 3-month follow-up. For the primary endpoints at 3 months, no significant changes were observed in CAT scores (from 11.2 to 11.0, P = .87), body weight (from 48.6 to 48.8 kg, P = .32), or NK cell activity (from 42.6% to 43.9%, P = .58). SDS scores showed significant improvement at 3 months (from 42.2 to 38.5, P = .032) and 12 months (from 42.2 to 40.4, P = .034). Conclusion: Jiinshihoto did not improve respiratory symptoms, weight, or NK cell activity in patients with pulmonary MAC ineligible for standard treatment but may be beneficial for depressive symptoms.

  • The 2022 revised diagnostic criteria for IgG4-related respiratory diseases

    by Tomohiro Handa, Shoko Matsui, Hiroshi Yamamoto, Yuko Waseda, Tae Iwasawa, Takeshi Johkoh, Kenji Notohara, Akira Hebisawa


  • Identifying Problems in the Morphological Evaluation of Bronchoalveolar Lavage

    by Y. Waseda, A. Takeuchi, Y. Hosokawa, S. Kimura, K. Yamaoka, M. Mitsui, A. Shimada, M. Yamaguchi, T. Sonoda, C. Honjo, et al.

  • Open Access

    Jiinshihoto may improve immunity by improving depression in patients with mild pulmonary Mycobacterium avium-intracellulare complex disease: a preliminary study

    by Makiko Yamaguchi, Yuko Waseda, Keiko Ogawa-Ochiai, Satomi Kimura, Koji Yamaoka, Kosuke Kurokawa, Ryo Chikazawa, Toshihiro Takeda, Masayuki Sato, Koki Nakashima, et al.

    Background: In Japan, pulmonary Mycobacterium avium-intracellulare complex (MAC) disease is highly prevalent. This study aimed to evaluate the efficacy of Jiinshihoto (JST) for treating pulmonary MAC disease. Methods: Twenty-four patients, not receiving standard treatment for pulmonary MAC disease, were enrolled in this study; of these, 21 patients (3 patients dropped out of the study) were eligible and selected to participate. They were administered JST (3.0 g; Tsumura Co., Tokyo, Japan) three times per day for 12 months. Their weight, chronic obstructive pulmonary disease assessment test (CAT) score, NK cell activity, chest computed tomography (CT) results, blood sample results, Self-rating Depression Scale (SDS) scores, and State-Trait Anxiety Inventory (STAI) scores were measured: (i) before JST administration, (ii) after 3 months, and (iii) at the end of the study. Results: Before JST administration, the exacerbation group (n = 10 patients; 6 patients with worsened conditions at the end of the study and 4 patients who were switched to standard treatment during the study because of exacerbation) had a significantly low body mass index (BMI), mild depression, and high anxiety. The overall patient population showed no significant differences in the chronic obstructive pulmonary disease assessment score, body weight, or natural killer cell activity after 3 months of treatment; however, the SDS score improved significantly. At the end of treatment, the nutritional scores had worsened, but the SDS score improved significantly. Specifically, the SDS scores improved significantly only in the non-exacerbation group (n = 11 patients), and natural killer cell activity improved in the non-exacerbation group. Additionally, a comparison of the data of both groups before and after JST administration showed that the exacerbation group had significantly lower BMI and worse CT scores when using a BMI cutoff of 18.4 (sensitivity, 81.8%; specificity, 70%). Conclusion: Patients with a high BMI and low CT score at the time of initial diagnosis may benefit from JST treatment, which may significantly improve depression and immunity and prevent disease progression. Therefore, JST may be an effective treatment in selected pulmonary MAC patients. Trial registration: This study has been registered in the UMIN-Clinical Trials Registry (UMIN000033590, August 1, 2018).

  • Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan

    by Shu Hisata, Masashi Bando, Sakae Homma, Kensuke Kataoka, Takashi Ogura, Shinyu Izumi, Susumu Sakamoto, Kizuku Watanabe, Yoshinobu Saito, Yasuo Shimizu, et al.


  • Open Access

    Chest computed tomography findings of adult patients with antimelanoma differentiation-associated protein 5 antibody-positive interstitial lung disease

    by Yuko Waseda, Takeshi Johkoh, Helmut Prosch, Stefan Nemec, Keigo Saeki, Satoshi Watanabe, Yasuhito Hamaguchi, Akira Shiraki, Yoshinao Muro, Masahide Yasui, et al.

    Objectives: Interstitial lung disease (ILD) associated with the antimelanoma differentiation-associated protein 5 (anti-MDA5) antibody is a rapidly progressive disease that requires timely, aggressive treatment. However, prompt diagnosis is difficult due to the longer time required for antibody detection. This study described the computed tomography (CT) findings of anti-MDA5 antibody-positive ILD (anti-MDA5-ILD). Methods: CT findings of 20 patients (7 men, 13 women; mean age, 53.6 ± 13.5 years) with anti-MDA5-ILD were retrospectively reviewed. All patients had clinical diagnoses of dermatomyositis, and 14 patients presented with amyopathic findings. Results: Bilateral ground-glass attenuation, air-space consolidation, and reticular shadows were observed in 20 (100%), 15 (75%), and 3 (15%) patients, respectively. The spread of air-space consolidation was 6.0 ± 5.6% (mean ± standard deviation). Univariate analysis revealed that high Krebs von den Lungen-6, high spread of consolidation, low partial pressure of oxygen, and low forced vital capacity were significant predictors for poor survival. The final radiological diagnoses were nonspecific interstitial pneumonia and organising pneumonia (OP) in 2 (10%) and 16 (80%) patients, respectively. Further, 30% of OP patients showed fibrosis. Conclusion: The characteristic CT findings of patients with anti-MDA5-ILD were ground-glass attenuation, air-space consolidation, and less reticulation. These CT findings were compatible with those of OP.


  • Open Access

    Myositis-Related Interstitial Lung Disease: A Respiratory Physician’s Point of View

    by Yuko Waseda

    Idiopathic inflammatory myositis (IIM) is an umbrella term for diseases of unknown origin that cause muscle inflammation. Dermatomyositis and polymyositis are IIMs that commonly cause interstitial lung disease (ILD). When a patient presents with ILD, the evaluation of whether the case displays the characteristics of myositis should be determined by interview, physical examination, imaging findings, the measurement of myositis-related antibodies, and the determination of disease severity after diagnosis. Rapidly progressing anti-melanoma differentiation-associated gene 5 antibody-positive ILD may require rapid multi-drug therapy, while anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD can be treated with anti-inflammatory drugs. Importantly, however, anti-ARS antibody-positive ILD often recurs and sometimes develops into fibrosis. Early diagnosis is crucial for treatment, and we therefore need to clarify the features of myositis associated with ILD and suspect these pathologies early. This section reviews what clinicians need to look for and what findings are evaluated in patients when diagnosing myositis associated with ILD.


  • Open Access

    Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia

    by Yuko Waseda, Masahide Yasui, Kousuke Kurokawa, Ryo Chikazawa, Toshihiro Takeda, Miho Mitsui, Tomoaki Sonoda, Makiko Yamaguchi, Satoshi Watanabe, Hazuki Takato, et al.

    Background: Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biomarkers. Methods: The study included 22 and 16 patients diagnosed with b- and d-pneumonia, respectively, at our institution or affiliated institutions. For d-pneumonia, the causative drug was minocycline hydrochloride in four patients, gefitinib in two patients, nivolumab in two patients, pembrolizumab in two patients, sulfasalazine in two patients, loxoprofen in one patient, Bouiougitou in one patient, edoxaban tosilate hydrate in one patient, and abemaciclib in one patient. White blood cell (WBC), C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), surfactant protein (SP)-D, and SP-A levels were measured in each patient and compared between the groups. Results: Significant differences were noted in the WBC and SP-D levels between the two groups (P < 0.05, P < 0.001), but not in the CRP, KL-6, or SP-A levels. Conclusion: The study results suggest that SP-D is a useful marker for differentiating b-pneumonia and d-pneumonia.


  • Open Access

    The pronounced lung lesions developing in LATY136F knock-in mice mimic human IgG4-related lung disease

    by Yuko Waseda, Kazunori Yamada, Keishi Mizuguchi, Kiyoaki Ito, Satoshi Watanabe, Masahiko Zuka, Tamotsu Ishizuka, Marie Malissen, Bernard Malissen, Mitsuhiro Kawano, et al.

    Rationale: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a novel clinical disease entity characterized by an elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. Pathological changes are most frequently seen in the pancreas, lacrimal glands, and salivary glands, but pathological changes in the lung also exist. Linker for activation of T cell (LAT)Y136F knock-in mice show Th2-dominant immunoreactions with elevated serum IgG1 levels, corresponding to human IgG4. We have reported that LATY136F knock-in mice display several characteristic features of IgG4-RD and concluded that they constitute an appropriate model of human IgG4-RD in salivary glands, pancreas, and kidney lesions. Objectives: The aim of this study is to evaluate whether lung lesions in LATY136F knock-in mice can be a model of IgG4-related lung disease. Methods: Lung tissue samples from LATY136F knock-in mice (LAT) and wild-type mice (WT) were immunostained for IgG1 and obtained for pathological evaluation, and cell fractions and cytokine levels in broncho-alveolar lavage fluid (BALF) were analyzed. Results: In the LAT group, IgG1-positive inflammatory cells increased starting at 4 weeks of age and peaked at 10 weeks of age. The total cell count and percentage of lymphocytes increased significantly in BALF in the LAT group compared to the WT group. In BALF, Th2-dominant cytokines and transforming growth factor-β were also increased. In the LAT group, marked inflammation around broncho-vascular bundles peaked at 10 weeks of age. After 10 weeks, fibrosis around broncho-vascular bundles and bronchiectasis were observed in LATY136F knock-in mice but not WT mice. Conclusions: LATY136F knock-in mice constitute an appropriate model of lung lesions in IgG4-RD.